CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Deferred Income Tax Expense (Benefit)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Deferred Income Tax Expense (Benefit) of -$75.37 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for the quarter ending 2011-03-26 was $3.42M, a 165.27% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for the quarter ending 2010-12-25 was -$39.20M, a 643.31% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for the quarter ending 2010-09-25 was -$108.00K.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for the quarter ending 2010-06-26 was $465.00K.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for fiscal 2025 was -$75.37M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for fiscal 2024 was -$67.19M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for fiscal 2023 was -$51.35M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. deferred income tax expense (benefit) for fiscal 2022 was -$33.11M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-27 | -$75.37M 10-K · filed 2026-02-18 | ||||
| 2024-12-28 | -$67.19M 10-K · filed 2026-02-18 | ||||
| 2023-12-30 | -$51.35M 10-K · filed 2026-02-18 | ||||
| 2022-12-31 | -$33.11M 10-K · filed 2025-02-19 | ||||
| 2021-12-25 | -$20.31M 10-K · filed 2024-02-14 | ||||
| 2020-12-26 | $1.58M 10-K · filed 2023-02-22 | ||||
| 2019-12-28 | -$21.48M 10-K · filed 2022-02-16 | ||||
| 2018-12-29 | -$10.32M 10-K · filed 2021-02-17 | ||||
| 2017-12-30 | $27.99M 10-K · filed 2020-02-11 | ||||
| 2016-12-31 | $3.15M 10-K · filed 2019-02-13 | ||||
| 2015-12-26 | $4.31M 10-K · filed 2018-02-13 | ||||
| 2014-12-27 | $8.83M 10-K · filed 2017-02-14 | ||||
| 2013-12-28 | -$531.00K 10-K · filed 2016-02-12 | ||||
| 2012-12-29 | $1.31M 10-K · filed 2015-02-17 | ||||
| 2011-12-31 | -$8.67M 10-K · filed 2014-02-25 | ||||
| 2011-03-26 | $3.42M 10-Q · filed 2011-05-04 | -$35.78M derived: sum of 2 quarters · filed 2013-02-27 | -$35.89M derived: sum of 3 quarters · filed 2013-02-27 | -$35.42M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2010-12-25 | -$39.20M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$39.31M derived: sum of 2 quarters · filed 2013-02-27 | -$38.84M derived: sum of 3 quarters · filed 2013-02-27 | -$37.55M 10-K · filed 2013-02-27 | -$42.34M 10-K · filed 2011-02-23 |
| 2010-09-25 | -$108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | $357.00K derived: sum of 2 quarters · filed 2010-11-04 | $1.65M 10-Q · filed 2010-11-04 | $8.86M derived: sum of 4 quarters · filed 2012-02-27 | |
| 2010-06-26 | $465.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | $1.75M 10-Q · filed 2010-08-03 | $8.97M derived: sum of 3 quarters · filed 2012-02-27 | $7.63M derived: sum of 4 quarters · filed 2012-02-27 | |
| 2010-03-27 | $1.29M 10-Q · filed 2011-05-04 | $8.51M derived: sum of 2 quarters · filed 2012-02-27 | $7.17M derived: sum of 3 quarters · filed 2012-02-27 | ||
| 2009-12-26 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $5.88M derived: sum of 2 quarters · filed 2012-02-27 | $17.02M 10-K · filed 2012-02-27 | $16.84M 10-K · filed 2011-02-23 | |
| 2009-09-26 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | $9.81M 10-Q · filed 2010-11-04 | |||
| 2009-06-27 | $11.15M 10-Q · filed 2010-08-03 | ||||
| 2008-12-27 | $7.87M 10-K · filed 2011-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |